Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to glioblastoma multiforme treatment market will help companies and investors design strategic landscapes.
The frequency of intracranial neoplasms was studied by the National Institute of Neurology and Neurosurgery of Mexico (1987–1994). In this period, 1,776 patients with brain cancer received treatment, wherein 24% of them were diagnosed with pituitary adenoma and 33% with gliomas, with 28% of gliomas being GBM.
The mean survival was 16 months for GBM patient group. The healthcare system of Mexico is well structured with more than 84% of the residents insured either under public insurance scheme or have purchased private insurance. The country has spent ~5.5% of its GDP on healthcare in 2019, a slight increase from the 2018 (5.4%). The country’s investment in R&D activities is low (~1%).
Horizon Databook provides a detailed overview of country-level data and insights on the Mexico glioblastoma multiforme treatment market , including forecasts for subscribers. This country databook contains high-level insights into Mexico glioblastoma multiforme treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account